Effects of Dapagliflozin on Renal Function in Type 1 Diabetes Patients in the Real World: A Retrospective Multicenter Study of the KAMOGAWA-A Cohort

•The effects of SGLT2 inhibitors on renal function in patients with type 1 diabetes are unknown.•This study aimed to investigate the effects of dapagliflozin on renal function in patients with type 1 diabetes in the real world.•The decline in eGFR was significantly lower in the dapagliflozin group than in the non-use group at 24 months in Japanese patients with type 1 diabetes.•HbA1c level, total insulin dose, and UACR change were significantly lower in the dapagliflozin group than in the non-use group after 24 months.•The frequency of DKA was similar between the two groups.